eczema

Money present
Biotech

Apogee bags $1.3B royalty funding deal to advance eczema hopeful

Apogee has secured a promise of up to $1.3 billion from Blackstone Life Sciences as the biotech gears up to take its anti-IL-13 antibody into phase 3.
James Waldron May 27, 2026 8:57am
Metallic arrow symbols illuminated by blue and magenta lights forming a graph on blue and magenta background

Connect’s Dupixent rival hits the mark in phase 3 eczema trial

Mar 30, 2026 9:32am
target reach ladder climb meet win beat competition

Apogee data drive hype as threat to Lilly, Sanofi becomes clear

Mar 23, 2026 9:00am
Completing steps towards success checkmark on cubes symbolizing progress

Nektar eczema asset 'checked all of the boxes' in phase 2

Feb 10, 2026 10:55am
Graphic image of an arrow nailing the bullseye of a target

Evommune's Dupixent-like eczema data drive 75% stock rally

Feb 10, 2026 9:31am
Return To Sender stamp on an envelope

Amgen exits $400M autoimmune pact after running vast program

Jan 30, 2026 8:55am